2-methylene-4,6-androstadiene-3,17-dione

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 类固醇和类固醇衍生物
• 英文名称: 2-methylene-4,6-androstadiene-3,17-dione
• 英文别名: (8R,9S,10R,13S,14S)-10,13-dimethyl-2-methylidene-1,8,9,11,12,14,15,16-octahydrocyclopenta[a]phenanthrene-3,17-dione
• 化学式: C₂₀H₂₄O₂
• 分子量: 296.409
• InChiKey: YZXVILOHAJREMH-UKSSEWCLSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.4
• 重原子数：
  22
• 可旋转键数：
  0
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.6
• 拓扑面积：
  34.1
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  聚合甲醛 、 4,6-雄烯二醇-3,17-二酮 在 溶剂黄146 作用下， 反应 5.0h， 以74%的产率得到2-methylene-4,6-androstadiene-3,17-dione
  参考文献：
  名称：

  Osipowicz, Bronislawa; Jablonski, Leszek; Mejer, Stanislaw, Polish Journal of Chemistry, 1986, vol. 60, # 1-3, p. 311 - 313

  摘要：

  DOI：

文献信息

• Inhibitors of type 5 and type 3 17beta-hydroxysteroid dehydrogenase and methods for their use
  申请人：Endorecherche, Inc.

  公开号：US20040082556A1

  公开（公告）日：2004-04-29

  Novel methods of medical treatment and/or inhibition of development of diseases are disclosed for diseases that are sensitive to androgenic or estrogenic activity. The treatments utilize inhibitors of type 5 and/or type 3 17&bgr;-hydroxysteroid dehydrogenase. Novel inhibitors of type 5 17&bgr;-hydroxysteroid dehydrogenase are also disclosed, as are novel inhibitors of type 3 17&bgr;-hydroxysteroid dehydrogenase.

  本发明揭示了一种针对对雄激素或雌激素活性敏感的疾病的新型医疗治疗和/或抑制疾病发展的方法。这些治疗方法利用了类型5和/或类型3的17β-羟基类固醇脱氢酶的抑制剂。本发明还揭示了新型的类型5 17β-羟基类固醇脱氢酶抑制剂，以及新型的类型3 17β-羟基类固醇脱氢酶抑制剂。
• Inhibitors of type 5 and 3 17beta-hydroxysteroid dehydrogenase and methods for their use
  申请人：Endorecherche Inc.

  公开号：EP1321146A2

  公开（公告）日：2003-06-25

  Novel methods of medical treatment and/or inhibition of development of diseases are disclosed for diseases that are sensitive to androgenic or estrogenic activity. The treatments utilize inhibitors of type 5 and/or type 3 17β-hydroxysteroid dehydrogenase. Novel inhibitors of type 5 17β-hydroxysteroid dehydrogenase are also disclosed, as are novel inhibitors of type 3 17β-hydroxysteroid dehydrogenase.

  针对对雄激素或雌激素活性敏感的疾病，公开了新的医疗和/或抑制疾病发展的方法。这些治疗方法利用了 5 型和/或 3 型 17β- 羟类固醇脱氢酶的抑制剂。还公开了 5 型 17β- 羟类固醇脱氢酶的新型抑制剂，以及 3 型 17β- 羟类固醇脱氢酶的新型抑制剂。
• INHIBITORS OF TYPE 5 AND TYPE 3 17beta-HYDROXYSTEROID DEHYDROGENASE AND METHODS FOR THEIR USE
  申请人：Endorecherche Inc.

  公开号：EP1094798A2

  公开（公告）日：2001-05-02
• [EN] INHIBITORS OF TYPE 5 AND TYPE 3 17 beta -HYDROXYSTEROID DEHYDROGENASE AND METHODS FOR THEIR USE<br/>[FR] INHIBITEURS DE LA 17 beta -HYDROXYSTEROIDE DESHYDROGENASE DU TYPE 5 ET DU TYPE 3 ET METHODES D'UTILISATION ASSOCIEES
  申请人：——

  公开号：WO1999046279A2

  公开（公告）日：1999-09-16

  [EN] Novel methods of medical treatment and/or inhibition of development of diseases are disclosed for diseases that are sensitive to androgenic or estrogenic activity. The treatments utilize inhibitors of type 5 and/or type 3 17 beta -hydroxysteroid dehydrogenase. Novel inhibitors of type 5 17 beta -hydroxysteroid dehydrogenase are also disclosed, as are novel inhibitors of type 3 17 beta -hydroxysteroid dehydrogenase.
  [FR] L'invention concerne de nouvelles méthodes de traitement médical et/ou d'inhibition du développement de maladies, lesquelles méthodes concernent des maladies sensibles à l'activité androgène et oestrogène. Lesdits traitements font appel à des inhibiteurs de la 17 beta -hydroxystéroïde déshydrogénase du type 5 et/ou du type 3. L'invention concerne également de nouveaux inhibiteurs de la 17 beta -hydroxystéroïde déshydrogénase du type 5 et de nouveaux inhibiteurs de la 17 beta -hydroxystéroïde déshydrogénase du type 3.
• [EN] PROCESS FOR THE PREPARATION OF DROSPIRENONE<br/>[FR] PROCÉDÉ DE PRÉPARATION DE DROSPIRÉNONE
  申请人：CHORISIS S R L

  公开号：WO2009059765A2

  公开（公告）日：2009-05-14

  The present invention describes a process for the preparation of drospirenone (I) using androstendione as a starting material. In particular, androstendione protected on carbonyl group in position 3 as an enol-ether is functionalized in position 16 with a sulfoxide group and the derivative thus obtained undergoes thermal elimination in alkaline to give androsta-4,15- diene-3, 17-dione (V) which is further transformed into Drospirenone (I).